Featured News

Growing up, Skylar Weitz was self-conscious and shy about having celiac disease – she didn’t like feeling different from her peers. Today, at 11 years old, five years after her…

A research study published in the journal, Science, may have established a link between reovirus and celiac disease. Although reovirus is considered a common and often harmless virus, the study, co-authored by CDF Medical Advisory Board member, Stefano Guandalini, MD, and CDF Research Committee member, Sonia Kupfer, MD, determined that the reovirus, T1L, in some cases, might be causing the immune system to attack harmless food molecules, like gluten, triggering celiac disease.

A research study published in the journal, Science, may have established a link between reovirus and celiac disease. Although reovirus is considered a common and often harmless virus, the study, co-authored…

23andMe has been approved by the FDA to offer direct-to-consumer genetic screening for a number of diseases, including celiac disease. Consumers are strongly cautioned to consult their physician

Celiac Disease Foundation welcomes the FDA announcement that 23andMe can offer accessible, lower-cost, direct-to-consumer genetic screening for a number of diseases, including celiac disease. Celiac disease is a serious, genetic,…

Celiac Disease Foundation is pleased to announce the release of Gluten-Free Marketplace 2.0, our completely updated, one-stop destination to search for all of your favorite gluten-free products, services, companies, and…

Celiac Disease Foundation is pleased to announce the release of Gluten-Free Marketplace 2.0, our completely updated, one-stop destination to search for all of your favorite gluten-free products, services, companies, and…

A year has passed since Celiac Disease Foundation launched its patient registry, iCureCeliac®. Since our launch, 2,300 participants have contributed their medical information and experiences living with celiac disease and…

ImmusanT, a Cambridge, MA-based biotechnology company, has announced that Nexvax2®, an immunotherapy drug designed to protect celiac disease patients from gluten exposure, has successfully completed a Phase 1b clinical trial…

The March 19, 2017 Summit brought patients and consumer advocates together with guideline developers, methodologists, and other stakeholders in the clinical guideline enterprise for the purpose of constructive dialogue and initiation of durable relationships between them.